Comparison of efficacy and toxicity according to etoposide and cytarabine dosing in BEAM conditioning followed by autologous stem cell transplantation in Hodgkin lymphoma-Reference-Cited by-同舟云学术

Comparison of efficacy and toxicity according to etoposide and cytarabine dosing in BEAM conditioning followed by autologous stem cell transplantation in Hodgkin lymphoma

Published:2023-08-24 Issue:13 Volume:64 Page:2178-2187
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Vély Agathe¹,Couturier Marie-Anne²,Delepine Pascal³,Le Calloch Ronan⁴,Ertault Marjan⁵,Gastinne Thomas⁶,Plichon Chloé⁷,Lebreton Anne⁸,Lester Marie-Antoinette⁹,Larhantec Gaelle¹⁰,Cormier Nicolas¹¹,Fouquet Sophie¹²,Houot Roch¹³,Tanguy-Schmidt Aline¹¹⁴¹⁵,Hunault-Berger Mathilde¹¹⁴¹⁵,Orvain Corentin¹¹⁴¹⁵

Affiliation:

1. Service d’Hématologie Clinique, Centre Hospitalier Universitaire de Angers, Angers, France

2. Service d’Hématologie Clinique, Centre Hospitalier Régional et Universitaire de Brest, Brest, France

3. Etablissement Français du Sang, Brest, France

4. Service d’Hématologie Clinique, Centre Hospitalier de Cornouaille, Quimper, France

5. Service d’Hématologie et thérapie cellulaire, Centre Hospitalier Universitaire de Tours, Tours, France

6. Service d’Hématologie Clinique, Centre Hospitalier Universitaire de Nantes, Nantes, France

7. Service de Pharmacie, Centre Hospitalier Universitaire de Tours, Tours, France

8. Service de Pharmacie, Centre Hospitalier Universitaire de Angers, Angers, France

9. Service de Pharmacie, Centre Hospitalier Universitaire de Rennes, Rennes, France

10. Service de Pharmacie, Centre Hospitalier Régional et Universitaire de Brest, Brest, France

11. Service de Pharmacie, Centre Hospitalier Universitaire de Nantes, Nantes, France

12. Etablissement Français du Sang, Angers, France

13. Service d’Hématologie Clinique, Centre Hospitalier Universitaire de Rennes, Rennes, France

14. Université d‘Angers, Inserm UMR 1307, CNRS UMR 6075, Nantes Université, Angers

15. Federation hospitalo-universitaire « Grand Ouest against Leukemia »

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2023.2251073

Reference27 articles.

1. Autologous bone marrow transplantation for patients with relapsed hodgkin's disease

2. The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight- year study of 155 patients

3. High-dose cyclophosphamide, carmustine, and etoposide followed by autologous peripheral stem cell transplantation for patients with relapsed Hodgkin's disease [published erratum appears in Blood 1991 Dec 15;78(12):3330]

4. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial

5. Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease.